Skip to content

Total Assets at other companies

Eli Lilly logo
Eli LillyLLY
$116.58B+30.4%
Amgen logo
AmgenAMGN
$92.5B+3.5%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$349.3M+62.1%
Immunome logo
ImmunomeIMNM
$619.79M+80.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$997M-13.8%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$472.67M-26.2%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%
Enterprise value$1.32B+288%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's total assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's total assets?
Bicara Therapeutics (BCAX) reported total assets of $553.6M in Q1 2026.
How has Bicara Therapeutics's total assets changed year-over-year?
Bicara Therapeutics's total assets increased by 15.8% year-over-year, from $478.08M to $553.6M.
What is the long-term trend for Bicara Therapeutics's total assets?
Over 2 years (2023 to 2025), Bicara Therapeutics's total assets has grown at a 35.7% compound annual growth rate (CAGR), from $233.98M to $430.99M.
What does total assets mean?
The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.